CuraVac, Inc. is a clinical-stage biopharmaceutical company focused on the development of a new class of immunotherapies for treating autoimmune and inflammatory diseases including myasthenia gravis (MG), multiple sclerosis (MS) and other diseases.
The company’s independent advisory board includes Jean-Paul Prieels, PhD, previously head of research at GSK Biologicals, Didier Hoch, PhD, previously chairman of Sanofi Pasteur MSD, Bruce Forrest, M.D., previously senior vice president at Wyeth Pharmaceuticals, and Prof. Marc de Baets, M.D., PhD, clinical neurologist and MG expert at Maastricht University Hospital.
CuraVac is the scientific coordinator and the commercial partner of the Myasterix consortium, which receives funding under the European Union’s Seventh Framework Program.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2003
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was CuraVac Europe founded?
CuraVac Europe was founded in 2003.
What industry is CuraVac Europe in?
CuraVac Europe operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is CuraVac Europe based?
CuraVac Europe is headquartered in Rixensart, Belgium.
Find investors for your startup like CuraVac Europe
Gritt sends AI-personalised outreach to each investor — from your Gmail